Vontobel Holding Ltd. Has $220,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Vontobel Holding Ltd. lowered its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 31.1% during the third quarter, Holdings Channel reports. The institutional investor owned 5,502 shares of the company’s stock after selling 2,483 shares during the quarter. Vontobel Holding Ltd.’s holdings in Ionis Pharmaceuticals were worth $220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mather Group LLC. acquired a new stake in shares of Ionis Pharmaceuticals during the 1st quarter valued at about $29,000. International Assets Investment Management LLC boosted its holdings in Ionis Pharmaceuticals by 2,048.9% during the first quarter. International Assets Investment Management LLC now owns 7,607 shares of the company’s stock valued at $334,000 after purchasing an additional 7,253 shares in the last quarter. Sunbelt Securities Inc. bought a new stake in shares of Ionis Pharmaceuticals in the 1st quarter valued at approximately $44,000. Diversified Trust Co acquired a new position in shares of Ionis Pharmaceuticals in the 1st quarter worth approximately $261,000. Finally, Commonwealth Equity Services LLC lifted its position in shares of Ionis Pharmaceuticals by 2.4% during the 1st quarter. Commonwealth Equity Services LLC now owns 21,974 shares of the company’s stock worth $953,000 after buying an additional 512 shares during the period. Institutional investors own 93.86% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Bank of America upped their price target on Ionis Pharmaceuticals from $67.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Needham & Company LLC reissued a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, August 2nd. BMO Capital Markets lowered shares of Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $67.00 to $60.00 in a research report on Friday, August 2nd. JPMorgan Chase & Co. raised their price objective on shares of Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Finally, Stifel Nicolaus increased their price target on Ionis Pharmaceuticals from $50.00 to $53.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $60.28.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $38.42 on Thursday. The firm has a market cap of $5.61 billion, a price-to-earnings ratio of -14.39 and a beta of 0.38. Ionis Pharmaceuticals, Inc. has a 12 month low of $35.95 and a 12 month high of $54.44. The company has a quick ratio of 7.51, a current ratio of 7.61 and a debt-to-equity ratio of 4.67. The stock has a 50-day moving average price of $42.74 and a 200 day moving average price of $43.15.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.47. Ionis Pharmaceuticals had a negative net margin of 44.90% and a negative return on equity of 115.66%. The company had revenue of $225.00 million during the quarter, compared to analysts’ expectations of $152.35 million. During the same quarter in the previous year, the company earned $0.60 EPS. Ionis Pharmaceuticals’s revenue was up 19.7% on a year-over-year basis. Research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.68 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Richard S. Geary sold 2,430 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $48.00, for a total value of $116,640.00. Following the transaction, the executive vice president now owns 85,508 shares of the company’s stock, valued at $4,104,384. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders sold 2,803 shares of company stock valued at $134,402. Company insiders own 2.71% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.